Abstract 350P
Background
Currently, various chemotherapy regimens have been reported for the efficacy of unresectable squamous cell carcinoma (cSCC). However, there is no clear consensus. Here, we report the treatment results of unresectable cSCC in which concurrent chemoradiotherapy (CCRT) combining low-dose cisplatin and 5-fluorouracil (low-dose FP therapy) was performed in our department.
Methods
A two-year retrospective study was conducted for 23 patients who had been received CCRT with low-dose FP therapy for unresectable cSCC. The patient age ranged from 44 to 79 years (mean age, 71 years), and gender was 17 men and 6 women. The primary lesions of unresectable cSCC were present in 7 cases in the head and neck, in 1 case in the upper limbs, in 5 cases in the lower limbs, and in 10 cases in the perineal region. Radiotherapy (RT) of CCRT had irradiated the primary lesion and regional lymph nodes. And for chemotherapy of CCRT, low-dose FP therapy was used.
Results
When 23 patients were classified by TNM staging (UICC 8th), stage 3 of unresectable cSCC was 5 patients (21.7%) and stage 4 was 18 patients (78.3%). 6 cases who those with stage 4 were dead (26.1%), while there were no dead cases who those with stage 3. Overall response rate (ORR) was 81 %, and median progression-free survival (PFS) was 392 days. For stage 4 of unresectable cSCC, one-year overall survival (OS) was 78 %, two-year OS was 56.7%, median survival time (MST) was 560 days.
Conclusions
CCRT with low-dose FP therapy is an effective treatment for unresectable cSCC. However, tumors of the primary lesion and / or regional lymph nodes may remain after CCRT. In such cases, chemotherapy (i.e., maintenance therapy [MT]) should be continued after CCRT. In our department, most cases of unresectable cSCC receive MT after CCRT. Therefore, in the first treatment of unresectable cSCC, it is important how to make the tumor smaller. In this study, our cases had optimal results of ORR, median PFS, OS, and MST. According to these facts and results, we considered CCRT with low-dose FP therapy suppressed cSCC and is an effective treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
397P - Development of prediction model for hepatocellular carcinoma in chronic hepatitis B patients
Presenter: Teerapat Ungtrakul
Session: Poster display session
Resources:
Abstract
398P - Planning for future cancer control programs in Uganda: Projections of top five cancers’ incidence in the next decade
Presenter: Judith Asasira
Session: Poster display session
Resources:
Abstract
399P - Prevalence of colorectal cancer risk factors in apparently healthy adults in Suluhan Village, Bali
Presenter: Cindy Trisina
Session: Poster display session
Resources:
Abstract
400P - Female lung cancer: Emerging issue in Bangladesh
Presenter: Muhammad Rafiqul Islam
Session: Poster display session
Resources:
Abstract
402P - Work-related outcomes among cancer survivors in Singapore
Presenter: Chia Jie Tan
Session: Poster display session
Resources:
Abstract
407P - Focal treatments for metastatic soft tissue sarcoma (mSTS) is associated with improved overall survival
Presenter: Ching Tso Chen
Session: Poster display session
Resources:
Abstract
408P - The Asian sarcoma consortium sarcoma preceptorship program: A program evaluation study utilizing the Kirkpatrick model (Level 1 and 2)
Presenter: Fernando Gracieux Jr.
Session: Poster display session
Resources:
Abstract
409P - Integrated genomic and transcriptomic analysis revealed mutagenic patterns of dedifferentiated liposarcoma and leiomyosarcoma in Chinese patients
Presenter: Yuhong Zhou
Session: Poster display session
Resources:
Abstract
410P - Treatment patterns and outcomes of elderly patients with metastatic soft tissue sarcomas (mSTS)
Presenter: Yu-ju Kuo
Session: Poster display session
Resources:
Abstract
411P - Comparative analysis of protein profiles of prognosis-associated proteins and KIT-related proteins in gastrointestinal stromal tumour
Presenter: Yoshiyuki Suehara
Session: Poster display session
Resources:
Abstract